Drugs / Influvactetra
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT06824779 | Dec 2025 overdue | — | University Hospital of Saint-Etienne | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06141655 | Oct 2023 → May 2025 | influenza | Federico Martinón Torres | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT03630523 | Oct 2018 → Jan 2019 | PTEN hamartoma tumor syndrome | Radboud University Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT05048589 Comparator | Oct 2021 → May 2022 | influenza | Tor Biering-Sørensen | Completed | No outcome recorded |
| Phase 4 | NCT05154383 Comparator | Nov 2021 → Jul 2022 | — | Centre Hospitalier Annecy Genevois | Completed | No outcome recorded |
| Phase 4 | NCT06716567 Comparator | Nov 2020 → Nov 2023 | influenza | Centre Hospitalier Universitaire Saint Pierre | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influvactetra | “Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.” NCT06716567 ↗5“Flu vaccination by one of FLU vaccines in the french market : FluarixTetra® (GSK), VaxigripTetra® (Sanofi-Pasteur), Influvac Tetra® (VIATRIS MEDICAL)” NCT06824779 ↗ “the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used” NCT05048589 ↗ “One injection of the standard-dose Influvactetra vaccine will be given to the patient” NCT05154383 ↗ “INFLUVAC TETRA, Suspension for injection, one dose” NCT06141655 ↗ |
| Modality | Vaccine | “Tetravalent seasonal flu vaccination 2018/2019” NCT03630523 ↗ |